SirPAD Analysis to Examine Sirolimus-Coated Balloon Treatment for Femoropopliteal Artery Disease #Sirolimus #BalloonAngioplasty #PeripheralArteryDisease #Femoropopliteal #PAD
SirPAD Analysis to Examine Sirolimus-Coated Balloon Treatment for Femoropopliteal Artery Disease
LAS VEGAS — A new analysis from the SirPAD randomised clinical trial will examine the use of a sirolimus-coated balloon in patients with femoropopliteal peripheral artery disease (PAD) and intermittent claudication, focusing on a group for whom treatment is intended to improve symptoms as well as prevent serious limb complications. The findings are scheduled to …
dlvr.it
September 24, 2026 at 6:34 PM
SirPAD Analysis to Examine Sirolimus-Coated Balloon Treatment for Femoropopliteal Artery Disease #Sirolimus #BalloonAngioplasty #PeripheralArteryDisease #Femoropopliteal #PAD
Groundbreaking Findings on Femoropopliteal Arterial Disease Revealed at VIVA 2026#USA#Las_Vegas#Concept_Medical#SirPAD_Study#Femoropopliteal_PAD
Groundbreaking Findings on Femoropopliteal Arterial Disease Revealed at VIVA 2026
The SirPAD study highlights significant results for patients with femoropopliteal arterial disease at VIVA 2026, presenting vital insights for effective treatment.
third-news.com
September 21, 2026 at 11:55 AM
Groundbreaking Findings on Femoropopliteal Arterial Disease Revealed at VIVA 2026#USA#Las_Vegas#Concept_Medical#SirPAD_Study#Femoropopliteal_PAD
New Insights Revealed at VIVA 2026 About Peripheral Artery Disease Treatments#USA#Las_Vegas#Concept_Medical#Peripheral_Artery_Disease#VIVA_Congress
New Insights Revealed at VIVA 2026 About Peripheral Artery Disease Treatments
At the VIVA 2026 congress, groundbreaking findings regarding femoropopliteal PAD treatments will be presented, offering hope for patients.
third-news.com
September 21, 2026 at 11:20 AM
New Insights Revealed at VIVA 2026 About Peripheral Artery Disease Treatments#USA#Las_Vegas#Concept_Medical#Peripheral_Artery_Disease#VIVA_Congress
New Insights into Femoropopliteal Peripheral Artery Disease from SirPAD Study at VIVA 2026 Conference#USA#Las_Vegas#Concept_Medical#MagicTouch_PTA#SirPAD_Study
New Insights into Femoropopliteal Peripheral Artery Disease from SirPAD Study at VIVA 2026 Conference
At the VIVA 2026 conference, the SirPAD study showcases significant findings on femoropopliteal artery disease treatments, enhancing patient outcomes.
third-news.com
September 21, 2026 at 11:10 AM
New Insights into Femoropopliteal Peripheral Artery Disease from SirPAD Study at VIVA 2026 Conference#USA#Las_Vegas#Concept_Medical#MagicTouch_PTA#SirPAD_Study
SirPAD Subgroup Study Highlights Innovative Treatment for Femoropopliteal PAD at VIVA 2026#United_States#Las_Vegas#Concept_Medical#MagicTouch_PTA#SirPAD_Study
SirPAD Subgroup Study Highlights Innovative Treatment for Femoropopliteal PAD at VIVA 2026
The SirPAD study at VIVA 2026 presents new insights on treating claudication due to femoropopliteal PAD, exploring the benefits of sirolimus-coated balloons.
third-news.com
September 21, 2026 at 8:24 AM
SirPAD Subgroup Study Highlights Innovative Treatment for Femoropopliteal PAD at VIVA 2026#United_States#Las_Vegas#Concept_Medical#MagicTouch_PTA#SirPAD_Study
From the latest issue: Sato and colleagues show that lipid-rich plaques identified by NIRS-IVUS are associated with worse 12-month limb outcomes after femoropopliteal endovascular therapy, highlighting #plaque composition as a key predictor of #MALE.
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
July 30, 2026 at 1:30 PM
From the latest issue: Sato and colleagues show that lipid-rich plaques identified by NIRS-IVUS are associated with worse 12-month limb outcomes after femoropopliteal endovascular therapy, highlighting #plaque composition as a key predictor of #MALE.
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
Drug Coated Balloon Angioplasty after Plain or Scoring Balloon for Vessel Preparation for Femoropopliteal Arterial Disease (DASBAD): A Randomised Controlled Trial www.sciencedirect.com/science/arti... #hvhebron #cv [Text complet]
Drug Coated Balloon Angioplasty after Plain or Scoring Balloon for Vessel Preparation for Femoropopliteal Arterial Disease (DASBAD): A Randomised Controlled Trial
Plain balloon angioplasty (PBA) remains the standard technique for vessel preparation in peripheral artery disease. This prospective, single centre, s…
www.sciencedirect.com
June 10, 2026 at 5:18 PM
Drug Coated Balloon Angioplasty after Plain or Scoring Balloon for Vessel Preparation for Femoropopliteal Arterial Disease (DASBAD): A Randomised Controlled Trial www.sciencedirect.com/science/arti... #hvhebron #cv [Text complet]
Online first: Sato and colleagues show that lipid-rich plaques identified by NIRS-IVUS are associated with worse 12-month limb outcomes after femoropopliteal endovascular therapy, highlighting plaque composition as a key predictor of MALE.
doi.org/10.1177/1358...
doi.org/10.1177/1358...
May 12, 2026 at 1:15 PM
Online first: Sato and colleagues show that lipid-rich plaques identified by NIRS-IVUS are associated with worse 12-month limb outcomes after femoropopliteal endovascular therapy, highlighting plaque composition as a key predictor of MALE.
doi.org/10.1177/1358...
doi.org/10.1177/1358...
Efemoral Medical's Promising Long-Term Results Reinforce Innovative Therapy in Femoropopliteal Disease#Efemoral_Medical#Vascular_Scaffold_System#Femoropopliteal_Disease
Efemoral Medical's Promising Long-Term Results Reinforce Innovative Therapy in Femoropopliteal Disease
Recent data from Efemoral Medical showcase the success of their innovative Vascular Scaffold System, achieving remarkable long-term results in patients diagnosed with femoropopliteal disease.
third-news.com
April 21, 2026 at 11:29 AM
Efemoral Medical's Promising Long-Term Results Reinforce Innovative Therapy in Femoropopliteal Disease#Efemoral_Medical#Vascular_Scaffold_System#Femoropopliteal_Disease
Rate-Dependent Mechanical Behavior of Human Femoropopliteal Arteries in Biaxial Testing https://www.biorxiv.org/content/10.64898/2026.04.09.717509v1
April 13, 2026 at 6:46 PM
Rate-Dependent Mechanical Behavior of Human Femoropopliteal Arteries in Biaxial Testing https://www.biorxiv.org/content/10.64898/2026.04.09.717509v1
Rate-Dependent Mechanical Behavior of Human Femoropopliteal Arteries in Biaxial Testing https://www.biorxiv.org/content/10.64898/2026.04.09.717509v1
April 13, 2026 at 6:46 PM
Rate-Dependent Mechanical Behavior of Human Femoropopliteal Arteries in Biaxial Testing https://www.biorxiv.org/content/10.64898/2026.04.09.717509v1
Sirolimus-coated DCBs are showing promise in PAD, with the SirPAD trial demonstrating improved hard outcomes—including lower rates of major adverse limb events vs. standard balloons. Douglas Drachman, MD, MSCAI, and Sahil Parikh, MD, FSCAI, share their thoughts➡️ https://ow.ly/fMt850YFI1I
#CardioSky
#CardioSky
Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD
For femoropopliteal and BTK patients, the sirolimus balloon was associated with fewer limb events at 1 year than POBA.
ow.ly
April 12, 2026 at 3:00 PM
Sirolimus-coated DCBs are showing promise in PAD, with the SirPAD trial demonstrating improved hard outcomes—including lower rates of major adverse limb events vs. standard balloons. Douglas Drachman, MD, MSCAI, and Sahil Parikh, MD, FSCAI, share their thoughts➡️ https://ow.ly/fMt850YFI1I
#CardioSky
#CardioSky
Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD
Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD
Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD
cmacahilig@crf.org
Thu, 04/02/2026 - 15:47
L.A. McKeown
For femoropopliteal and BTK patients, the sirolimus balloon was associated with fewer limb events at 1 year than POBA.
www.tctmd.com
April 2, 2026 at 7:57 PM
Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD
Drug-coated devices in CLTI
In a nationwide cohort of >100,000 patients undergoing femoropopliteal revascularisation, DCBs and DES were associated with lower risks of major amputation or death vs uncoated devices. #cardiosky
eurointervention.pcronline.com/article/safe...
In a nationwide cohort of >100,000 patients undergoing femoropopliteal revascularisation, DCBs and DES were associated with lower risks of major amputation or death vs uncoated devices. #cardiosky
eurointervention.pcronline.com/article/safe...
March 12, 2026 at 5:45 PM
Drug-coated devices in CLTI
In a nationwide cohort of >100,000 patients undergoing femoropopliteal revascularisation, DCBs and DES were associated with lower risks of major amputation or death vs uncoated devices. #cardiosky
eurointervention.pcronline.com/article/safe...
In a nationwide cohort of >100,000 patients undergoing femoropopliteal revascularisation, DCBs and DES were associated with lower risks of major amputation or death vs uncoated devices. #cardiosky
eurointervention.pcronline.com/article/safe...
Lecture 15: Peripheral Vascular Disease — Cardiovascular
Peripheral arterial disease represents atherosclerosis affecting non-coronary arteries, most commonly the lower extremities.
https://hibbertmed.com/lectures/year1/unit1.7_cardiovascular/lecture_15_peripheral_vascular_disease
Peripheral arterial disease represents atherosclerosis affecting non-coronary arteries, most commonly the lower extremities.
https://hibbertmed.com/lectures/year1/unit1.7_cardiovascular/lecture_15_peripheral_vascular_disease
February 20, 2026 at 5:33 PM
Lecture 15: Peripheral Vascular Disease — Cardiovascular
Peripheral arterial disease represents atherosclerosis affecting non-coronary arteries, most commonly the lower extremities.
https://hibbertmed.com/lectures/year1/unit1.7_cardiovascular/lecture_15_peripheral_vascular_disease
Peripheral arterial disease represents atherosclerosis affecting non-coronary arteries, most commonly the lower extremities.
https://hibbertmed.com/lectures/year1/unit1.7_cardiovascular/lecture_15_peripheral_vascular_disease
Member publication alert:
Computational Optimization of a Stent for the Femoropopliteal Artery
link.springer.com/article/10.1...
Computational Optimization of a Stent for the Femoropopliteal Artery
link.springer.com/article/10.1...
Computational Optimization of a Stent for the Femoropopliteal Artery - Annals of Biomedical Engineering
Purpose Clinical outcomes of peripheral artery disease (PAD) stenting, particularly in the highly dynamic regions of the femoropopliteal artery at the adductor hiatus and behind the knee, leave signif...
link.springer.com
January 18, 2026 at 8:15 PM
Member publication alert:
Computational Optimization of a Stent for the Femoropopliteal Artery
link.springer.com/article/10.1...
Computational Optimization of a Stent for the Femoropopliteal Artery
link.springer.com/article/10.1...
Optimizing stent design for the femoropopliteal artery addresses critical cardiovascular challenges and enhances patient treatment outcomes, showcasing the intersection of healthcare and design.
bioengineer.org/optimizing-s...
bioengineer.org/optimizing-s...
Optimizing Stent Design for Femoropopliteal Artery
A groundbreaking study has emerged in the field of biomedical engineering, focusing on the optimization of stent design specifically for the femoropopliteal artery. The research, conducted by a team
bioengineer.org
January 17, 2026 at 12:39 AM
Optimizing stent design for the femoropopliteal artery addresses critical cardiovascular challenges and enhances patient treatment outcomes, showcasing the intersection of healthcare and design.
bioengineer.org/optimizing-s...
bioengineer.org/optimizing-s...
Global Algorithm for the Endovascular Treatment of Chronic Femoropopliteal Lesions: An Interdisciplinary Expert Opinion Statement | JACC: Cardiovascular Interventions www.jacc.org/doi/10.1016/...
Global Algorithm for the Endovascular Treatment of Chronic Femoropopliteal Lesions: An Interdisciplinary Expert Opinion Statement
View all available purchase options and get full access to this article.
www.jacc.org
January 10, 2026 at 5:41 PM
Global Algorithm for the Endovascular Treatment of Chronic Femoropopliteal Lesions: An Interdisciplinary Expert Opinion Statement | JACC: Cardiovascular Interventions www.jacc.org/doi/10.1016/...
EXPERIMENTAL CHARACTERIZATION OF BALLOON ANGIOPLASTY IN HUMAN FEMOROPOPLITEAL ARTERIES WITH DIFFERENT CALCIUM BURDENS https://www.biorxiv.org/content/10.1101/2025.11.27.691029v1
December 2, 2025 at 1:46 AM
EXPERIMENTAL CHARACTERIZATION OF BALLOON ANGIOPLASTY IN HUMAN FEMOROPOPLITEAL ARTERIES WITH DIFFERENT CALCIUM BURDENS https://www.biorxiv.org/content/10.1101/2025.11.27.691029v1
EXPERIMENTAL CHARACTERIZATION OF BALLOON ANGIOPLASTY IN HUMAN FEMOROPOPLITEAL ARTERIES WITH DIFFERENT CALCIUM BURDENS https://www.biorxiv.org/content/10.1101/2025.11.27.691029v1
December 2, 2025 at 1:46 AM
EXPERIMENTAL CHARACTERIZATION OF BALLOON ANGIOPLASTY IN HUMAN FEMOROPOPLITEAL ARTERIES WITH DIFFERENT CALCIUM BURDENS https://www.biorxiv.org/content/10.1101/2025.11.27.691029v1
From the latest issue:
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
doi.org
November 14, 2025 at 10:01 PM
From the latest issue:
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Feed: "BIOENGINEER.ORG"
By: Bioengineer on Saturday, November 1, 2025
By: Bioengineer on Saturday, November 1, 2025
Assessing Femoropopliteal Arteries: Health vs. Revascularization
In a groundbreaking study, researchers led by Gostev, Osipova, and Volkova have unveiled new insights into the biomechanical properties of femoropopliteal arteries—vital conduits in the circulatory s
bioengineer.org
November 1, 2025 at 7:07 PM
Feed: "BIOENGINEER.ORG"
By: Bioengineer on Saturday, November 1, 2025
By: Bioengineer on Saturday, November 1, 2025
Among patients who underwent femoropopliteal index interventions for claudication, endovascular procedures were associated with lower rates of major amputation at 1 year compared with open surgical bypass approaches.
ja.ma/3Waun9t
ja.ma/3Waun9t
October 16, 2025 at 7:45 PM
Among patients who underwent femoropopliteal index interventions for claudication, endovascular procedures were associated with lower rates of major amputation at 1 year compared with open surgical bypass approaches.
ja.ma/3Waun9t
ja.ma/3Waun9t
Online First!
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
doi.org
October 7, 2025 at 10:30 PM
Online First!
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Missed it live? We’ve got you covered:
- Elegance 12-month results
- SPORTS 24-month outcomes
- Meta-analysis on femoropopliteal stenting
Leading voices in the field break it all down - don’t miss these insights.
Watch now: www.youtube.com/watch?v=gWaj...
- Elegance 12-month results
- SPORTS 24-month outcomes
- Meta-analysis on femoropopliteal stenting
Leading voices in the field break it all down - don’t miss these insights.
Watch now: www.youtube.com/watch?v=gWaj...
Drug Elution Data From Europe: A Review of Data Shown at LINC & Charing Cross
YouTube video by The VIVA Foundation
www.youtube.com
September 16, 2025 at 3:36 PM
Missed it live? We’ve got you covered:
- Elegance 12-month results
- SPORTS 24-month outcomes
- Meta-analysis on femoropopliteal stenting
Leading voices in the field break it all down - don’t miss these insights.
Watch now: www.youtube.com/watch?v=gWaj...
- Elegance 12-month results
- SPORTS 24-month outcomes
- Meta-analysis on femoropopliteal stenting
Leading voices in the field break it all down - don’t miss these insights.
Watch now: www.youtube.com/watch?v=gWaj...